Baillie Gifford Reduces $47M in Royalty Pharma plc ($RPRX)
Key Points
- Baillie Gifford changed its Royalty Pharma plc ($RPRX) stake by 5.0% last quarter, cutting to 16,155,677 shares worth $891.44 million.
- Wall Street's consensus rating on $RPRX is Strong Buy and an average price target of $59.25.
- $RPRX last traded around $55.18.
Baillie Gifford trimmed its position in Royalty Pharma plc ($RPRX) by 5.0% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,155,677 shares of Royalty Pharma plc after selling 853,091 shares during the quarter. Baillie Gifford's holdings in Royalty Pharma plc were worth $891.44 million as of its most recent filing.
Royalty Pharma plc ($RPRX) Stock
Royalty Pharma plc Earnings
Royalty Pharma plc Dividend
Analysts Set New Price Targets
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.